November 30, 2020

The Niche

Knoepfler lab stem cell blog

DLL3 antibody

3 min read

A stem cell biotech in the news this week was one that had mostly flown under the radar previously with aim to zap cancer stem cells. Stemcentrx has a focus on killing cancer stem cells as a novel approach to treating cancer. Antonio Regalado had a nice article yesterday on the company. He reports that Stemcentrx has around a half a billion in funding. It is valued in the billions. These are very unusual figures for a stem cell biotech. Stemcentrx is developing novel cancer therapeutics such …Read More